IMPLEMENTATION OF COMPREHENSIVE CRITERIA FOR DECISION MAKING PROCESS OF PRICING AND REIMBURSEMENT IN ALGERIA

被引：0
|
作者：
Aissaoui, A. [1 ]
Khelef, R. [2 ]
Ahmed, N. [2 ]
Redouane, S. [2 ]
Mokhtaria, B. [2 ]
机构：
[1] Paris Dauphine Univ, Paris 16, France
[2] ISPOR Chapter Algeria, Algiers 16, Algeria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
下载
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Kolasa, Katarzyna
    Zwolinski, Krzysztof M.
    Kalo, Zoltan
    Hermanowski, Tomasz
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [2] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Katarzyna Kolasa
    Krzysztof M. Zwolinski
    Zoltan Kalo
    Tomasz Hermanowski
    Orphanet Journal of Rare Diseases, 11
  • [3] Drug pricing and reimbursement decision making systems in Mongolia
    Dorj G.
    Sunderland B.
    Sanjjav T.
    Dorj G.
    Gendenragchaa B.
    Journal of Pharmaceutical Policy and Practice, 10 (1)
  • [4] DRUG PRICING AND REIMBURSEMENT PROCESSES IN ALGERIA
    Soualmi, R.
    Bouabidi, A.
    Djahdou, Z.
    Ziouani, S.
    Kaddar, M.
    Mansouri, K.
    VALUE IN HEALTH, 2016, 19 (07) : A448 - A449
  • [5] REIMBURSEMENT OF ORPHAN AND EXPENSIVE DRUGS IN THE NETHERLANDS: EXPLORATION OF ESSENTIAL CRITERIA IN THE DECISION MAKING PROCESS
    Tariq, L.
    Frederix, G. W.
    Roberts, R. W.
    van Bakel, P.
    Belitser, S., V
    Raaijmakers, J. A.
    Hovels, A. M.
    VALUE IN HEALTH, 2015, 18 (07) : A546 - A546
  • [6] EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION MAKING FOR ORPHAN DRUGS IN ASIA
    Tan, S.
    Dummett, H.
    Kirpekar, S.
    Guan, Q.
    Priest, V. L.
    VALUE IN HEALTH, 2012, 15 (07) : A621 - A622
  • [7] Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector?
    Kolasa, Katarzyna
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (05) : 751 - 762
  • [8] MEASURING THE IMPORTANCE OF DECISION MAKING CRITERIA FOR ANTICANCER DRUG REIMBURSEMENT IN KOREA
    Kwon, S.
    Park, S.
    Lee, E.
    VALUE IN HEALTH, 2015, 18 (07) : A477 - A477
  • [9] DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING
    Lemeshko, V
    Fedyaeva, V
    Musina, N. Z.
    Omelyanovskiy, V
    Khachatryan, G. R.
    VALUE IN HEALTH, 2018, 21 : S185 - S185
  • [10] Criteria of unresectability and the decision-making process
    Schulick, R. D.
    HPB, 2008, 10 (02) : 122 - 125
12345